Why Luminex Is Poised to Keep Plunging

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biological testing technologist Luminex (NASDAQ: LMNX  ) has received an alarming one-star ranking.

With that in mind, let's take a closer look at Luminex and see what CAPS investors are saying about the stock right now.

Luminex facts

Headquarters (founded)

Austin, Texas (1995)

Market Cap

$730.6 million


Life sciences tools and services

Trailing-12-Month Revenue

$202.6 million


CEO Patrick Balthrop Sr. (since 2004)
CFO Harriss Currie (since 2003)

Return on Equity (average, past 3 years)



$56.4 million / $2.8 million


Life Technologies

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 14% of the 106 members who have rated Luminex believe the stock will underperform the S&P 500 going forward.

Earlier this week, one of those bears, All-Star bclan13, succinctly summed up the bear case for our community:

Other technologies are coming in and taking away more and more of where Luminex's performance envelope has a competitive advantage (lab geeks' "mid-plex"). I see particular pressures in genetic disease testing. ... Longer term, there is a stable business for Luminex in [Human Leukocyte Antigens ] testing (particularly the protein tests) but this is not going to provide double digit growth forever -- a requirement of a company with this kind of valuation.

If you want market-topping returns, you need to protect yourself from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 08, 2013, at 1:00 PM, gerras wrote:

    As a physician, I know that the newly approved

    panel for quick diagnosis of several gastrointestional

    causes of common disorders is a first and a will be

    highly used product for in hospital and outpatient

    testing. Foolish to ignore its significance on top

    and bottom line of Luminex.


Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2244651, ~/Articles/ArticleHandler.aspx, 9/24/2016 5:15:30 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 19 hours ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
LMNX $22.79 Up +0.04 +0.18%
Luminex CAPS Rating: ****
AFFX.DL $14.01 Down +0.00 +0.00%
Affymetrix CAPS Rating: **
LIFE.DL $0.00 Down +0.00 +0.00%
Life Technologies… CAPS Rating: ***
SQNM $0.00 Down +0.00 +0.00%
Sequenom CAPS Rating: **